New Jersey Clinical Trials Report — June 2026

For New Jersey residents considering participation in clinical research, June 2026 presents a crucial window of opportunity, particularly for those interested in trials nearing their enrollment deadlines. Across the state, 106 clinical trials are slated to close within the next 90 days, meaning time is running out to explore these options. This includes 8 studies that are actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to investigate trials with impending deadlines. Research focusing on various conditions, particularly in oncology and cardiovascular health, are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (4 trials)
• Hypotension (3 trials)
• Major depressive disorder (2 trials)
• Central nervous system diseases (2 trials)
• Head and neck cancer (2 trials)
• Lung cancer (2 trials)
• Blood pressure (2 trials)
• Atrial fibrillation (2 trials)
• Cancer (2 trials)
• Cardiovascular diseases (2 trials)

New Horizons in New Jersey Research

This month, New Jersey welcomes 31 new clinical trials, a notable increase from the 24 trials that opened in May 2026. These new studies bring a range of opportunities, including significant Phase 3 drug trials from major sponsors, offering access to cutting-edge treatments and diagnostics for various health challenges.

Among the most notable new trials:

• Bayer is sponsoring NCT07672119, an observational study titled "A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide." This large study aims to enroll 3,000 participants to better understand the risk of serious heart-related problems in older men receiving common prostate cancer treatments. Prostate cancer is the most commonly diagnosed malignancy in U.S. men.
• For breast cancer patients, Novartis Pharmaceuticals is behind NCT07647042, "A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors." This study seeks 750 participants to describe treatment patterns and outcomes for those with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) early breast cancer.
• A critical Phase 3 trial, NCT07621796, is "Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant," sponsored by Hackensack Meridian Health. This study will randomize 660 participants with acute ischemic stroke and recent Direct Oral AntiCoagulant (DOAC) ingestion to receive either intravenous tenecteplase or a placebo, investigating a new approach to thrombolysis.
• AngioInsight is sponsoring NCT07676097, "Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study." This observational study aims to enroll 620 participants to establish the diagnostic performance of the AngioAI+ System for estimating fractional flow reserve (FFR) and detecting coronary microvascular disease (CMD).
• In another significant Phase 3 trial, PleoPharma, Inc. is leading NCT07644052, "Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder." This randomized, double-blind, placebo and active-controlled study will evaluate whether PP-01 can mitigate withdrawal symptoms in 420 adults discontinuing cannabis.
• Georgetown University is sponsoring NCT07618520, "Expanding Genetic Access for Prostate Cancer Survivors," which aims to enroll 500 participants to increase genetic education and testing for hereditary cancer risk among prostate cancer survivors.
• Memorial Sloan Kettering Cancer Center is behind NCT07619079, "Malignant Polyp Registry," seeking 500 participants to learn more about malignant colorectal polyps and the risk of cancer recurrence or spread after removal.
• PROCEPT BioRobotics is sponsoring NCT07650448, "WATER IV PCa (AS Sub-study)," a multicenter, prospective, randomized clinical trial evaluating the safety and efficacy of Aquablation therapy in 333 men with localized prostate cancer.

The 31 new trials opening this month cover a diverse range of health conditions. The most common conditions addressed by these new studies include:

• Prostate cancer (2 trials)
• Breast cancer (2 trials)
• Acute or chronic coronary artery disease (1 trial)
• Aging (1 trial)
• AML (1 trial)
• Anti-aging (1 trial)
• Blood pressure (1 trial)
• Cervical cancer screening (1 trial)
• Brain blood flow (1 trial)
• Bladder cancer (1 trial)

In terms of intervention types, drug trials lead the way, accounting for 13 of the new studies. Behavioral and device interventions are also well-represented, each with 6 new trials, alongside other types of research including radiation, combination products, biological treatments, and procedures.

Geographic Footprint of New Trials Across New Jersey

New Jersey's clinical research landscape remains robust, with 1,655 clinical trials currently recruiting across 162 cities and 1,084 research sites statewide. This month, new research initiatives are notably concentrated in several key areas. The cities with the highest number of new trials include:

• Basking Ridge (9 new trials)
• Montvale (9 new trials)
• Middletown (9 new trials)
• New Brunswick (5 new trials)

While these cities show a significant cluster of new opportunities, other areas are also expanding their research footprint, including Marlton (2), Newark (2), West Orange (2), Piscataway (2), Secaucus (1), and Shrewsbury (1). This distribution ensures that residents in various regions of New Jersey have access to cutting-edge research, with a strong presence in both established research hubs and emerging locations.

Who Can Participate? Eligibility and Leading Sponsors

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 31 new trials launched this month, 5 are actively seeking healthy volunteers. Statewide, a total of 130 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in New Jersey are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 27 include older adults, ensuring that research benefits this demographic. There are 3 female-only trials and 4 male-only trials, addressing gender-specific health concerns. Notably, 0 of the new trials include children as participants this month.

Academic institutions continue to play a vital role in the state's research ecosystem, with Memorial Sloan Kettering Cancer Center sponsoring 9 of the new trials and Rutgers, The State University of New Jersey sponsoring 5. Industry sponsors are also driving significant research efforts, with 9 new trials sponsored by pharmaceutical companies such as Bayer and PleoPharma, Inc., alongside other organizations like Hackensack Meridian Health, Georgetown University, and AngioInsight.

As we move through June, the focus will remain on the ongoing enrollment in these significant trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across New Jersey.